Novelix Pharmaceuticals Appoints Ms. Sridevi Belide as Non-Executive Non-Independent Director

Novelix Pharmaceuticals Limited has officially announced the appointment of Ms. Sridevi Belide as Non-Executive Non-Independent Director, marking a significant addition to the company's board composition. The appointment was formally approved by shareholders during an Extraordinary General Meeting held on January 9, 2026, with the effective date of appointment being October 23, 2025.

Director Profile and Qualifications

Ms. Sridevi Belide brings substantial healthcare expertise to the board, holding a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree. Her medical professional background positions her to contribute strategic insights in healthcare management, quality standards, and corporate governance areas that align with the pharmaceutical company's operations.

Appointment Details

The key details of the directorial appointment are outlined below:

Parameter:	Details
Director Name:	Ms. Sridevi Belide
DIN:	10455373
Position:	Non-Executive Non-Independent Director
Effective Date:	October 23, 2025
Approval Date:	January 9, 2026
Approval Method:	Extraordinary General Meeting

Regulatory Compliance

The appointment has been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that Ms. Belide is not debarred from holding the office of Director by any SEBI order or other regulatory authority, ensuring full compliance with BSE circular requirements.

Board Composition and Relationships

Ms. Belide belongs to the promoter group of the company but maintains no familial relationships with existing directors on the board. This appointment strengthens the company's board structure while maintaining appropriate governance standards. The company has provided comprehensive disclosure as required under SEBI regulations and relevant circulars.

Company Background

Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited, operates under CIN L67120TG1994PLC018956 and trades on BSE with scrip code 536565. The company is headquartered in Hyderabad, Telangana, and continues to expand its leadership team to support its pharmaceutical operations and strategic objectives.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.71%	-5.56%	+6.21%	+29.38%	+137.23%	+1,032.21%

Novelix Pharmaceuticals Limited has announced that its shareholders have approved the appointment of Ms. Sridevi Belide as Non-Executive Non-Independent Director during an Extraordinary General Meeting (EGM) held on January 9, 2026. The company, formerly known as Trimurthi Limited, communicated this development to BSE Limited on January 10, 2026.

Appointment Details

The key details of Ms. Belide's directorial appointment are outlined in the company's regulatory filing:

Parameter	Details
Director Name	Ms. Sridevi Belide
DIN	10455373
Position	Non-Executive Non-Independent Director
Effective Date	October 23, 2025
Approval Date	January 9, 2026 (EGM)
Relationship	Belongs to promoter group

Regulatory Compliance

Novelix Pharmaceuticals has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Ms. Belide is not related to any existing director and belongs to the promoter group of the company.

The filing also stated that Ms. Sridevi Belide is not debarred from holding the office of Director by any SEBI order or any other regulatory authority, ensuring compliance with BSE circular requirements.